GO
Loading...

Enter multiple symbols separated by commas

Stocks Pfizer Inc

More

  • July 28- Pfizer Inc reported better-than-expected quarterly profit and revenue, helped by strong demand for its pneumonia vaccine Prevnar 13 and sales of its breast cancer drug, Ibrance. The unit accounted for about 13 percent of Pfizer's total revenue. Pfizer's shares rose about 2 percent in premarket trading on Tuesday.

  • Panda bear market

    U.S. stocks have some powerful negatives tugging at them, not the least of which are the Shanghai "panda bear" market and a global commodities rout.

  • Dissecting big pharma's numbers: Pro Tuesday, 28 Jul 2015 | 7:44 AM ET
    Dissecting big pharma's numbers: Pro

    Barbara Ryan, Clermont Partners, breaks down Pfizer and Merck's quarterly results and shares her outlook on the pharmaceutical sector.

  • *Wall Street sank on Monday, for the fifth straight day, after the steepest decline in Chinese stocks in eight years increased concerns that cooling growth in the world's No. 2 economy could hurt China's trading partners. *With second-quarter reports well under way, analysts expect overall earnings of S&P 500 companies to dip 0.3 percent, below the 3- percent...

  • Pfizer revenue falls 7 percent Tuesday, 28 Jul 2015 | 7:06 AM ET

    July 28- U.S. drugmaker Pfizer Inc reported a 7 percent fall in quarterly revenue, hurt by a strong dollar. The company's net income fell to $2.63 billion, or 42 cents per share, in the second quarter, from $2.91 billion, or 45 cents per share, a year earlier. Revenue fell to $11.85 billion from $12.77 billion.

  • Mylan, whose shares fell 14.5 percent, said it would continue its own unsolicited pursuit of Irish drugmaker Perrigo Co, a maker of over-the-counter consumer and nutritional products and generic topical medicines. Perrigo is one of the few remaining assets out there, "said Morningstar analyst Michael Waterhouse. Other industry analysts expect Mylan will...

  • NEW YORK, July 27- Allergan CEO Brent Saunders said on Monday the company will use the $36 billion it nets from the sale of its generics business to Teva for more deals, including large, "transformational" merger opportunities. Saunders, who led the $66 billion combination of Actavis and Allergan that closed only a few months ago, told investors that it would use the...

  • Minefield for market with Fed, earnings, commodities Monday, 27 Jul 2015 | 8:08 AM ET
    An oil trader works on the floor of the New York Mercantile Exchange.

    The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.

  • What to expect from Merck & Pfizer tomorrow Monday, 27 Jul 2015 | 6:52 AM ET
    What to expect from Merck & Pfizer tomorrow

    CNBC's Dominic Chu reports on Kensho studies, looking at Merck and Pfizer's stock performances around quarterly reports.

  • SYDNEY/ HONG KONG, July 27- Asian shares began the week on a plaintive note amid losses on Wall Street and worries over China, while investors braced for a Federal Reserve meeting that might take another small step toward lifting U.S. interest rates. Financial spreadbetters expected Britain's FTSE 100 0.3 percent lower, Germany's to open 0.4 percent down, and...

  • SYDNEY, July 27- Asian shares began the week on a plaintive note amid losses on Wall Street and worries over China, while investors braced for a Federal Reserve meeting that might take another small step toward lifting U.S. interest rates. Japan's Nikkei slipped 0.5 percent, while MSCI's broadest index of Asia-Pacific shares outside Japan lost 0.8 percent.

  • *Most Asian stock markets lower tracking Wall St. SYDNEY, July 27- Asian shares began the week on a plaintive note amid losses on Wall Street and worries over China, while investors braced for a Federal Reserve meeting that might take another small step toward lifting U.S. interest rates. Japan's Nikkei slipped 0.8 percent in early trade, while MSCI's broadest...

  • The United States, New Zealand and Australia are pushing hard for Canada to open up its protected dairy market and allow more imports, complaining that the country has not given its trade partners a sign it is ready to talk and even mulling a TPP without Canada. Sugar refiner Imperial Sugar Co, part of Louis Dreyfus Commodities, says Australia should be allowed to...

  • Buy the dip? Here's the bullish case now Friday, 24 Jul 2015 | 1:53 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Two Strategists favor U.S. stocks vs. global stocks

  • Health care takes earnings hot hand into week ahead Friday, 24 Jul 2015 | 10:23 AM ET
    Pfizer headquarters in New York.

    Health-care stocks are batting 12 for 12 in beating earnings estimates. Will the streak last?

  • *Sanofi/ Regeneron PCSK9 drug Praluent endorsed by EMA. *Praluent to compete with Amgen's rival product Repatha. LONDON, July 24- A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators on Friday, two months behind a rival product from Amgen.

  • LONDON, July 24- A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators on Friday, two months behind a rival product from Amgen. Amgen's Repatha was formally approved by the European Commission on Tuesday after a positive EMA opinion in May and Praluent is likely to be cleared by the Commission after a...

  • July 23- Investment bank and asset manager Lazard Ltd reported a quarterly profit that handily beat analysts' estimate as a jump in corporate dealmaking boosted its M&A advisory fees. M&A and other advisory fees, which account for 45 percent of Lazard's operating revenue, rose 17 percent to $273.2 million in the second quarter ended June. Some of the big deals...

  • July 21- Amgen Inc's cholesterol fighting drug was approved by the European Commission, giving the keenly anticipated treatment a head start over a rival drug being developed by Regeneron Pharmaceuticals Inc and Sanofi SA. Amgen did not immediately reveal when the drug would be available or its pricing strategy. Amgen's drug is designed for biweekly doses of...

  • July 21- Novartis remains bullish about prospects for its blockbuster cancer drug Afinitor, which achieved sales of $1.58 billion last year, despite competitors lining up to challenge its market position. The success of Opdivo could, therefore, push back the use of Afinitor as doctors try the newer option, reducing sales of the Novartis product.